Society for Neuro-Oncology Annual Meeting 2019
Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM: Half-Way Report
AACR Annual Meeting 2019
Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth upon bevacizumab-induced hypoxia, in vivo
AACR Annual Meeting 2019
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting
AACR Annual Meeting 2019
Phase 2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma
AACR Annual Meeting 2019
Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of diffuse intrinsic pontine glioma (DIPG)
Society for NeuroOncology
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma
Society for NeuroOncology
Phase 1/2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma
Society for NeuroOncology
Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of diffuse intrinsic pontine glioma (DIPG)
Society for NeuroOncology
VAL-083 inhibits proliferation of a panel of eight glioblastoma stem cells: Downregulation of BRD4 as a novel anti-neoplastic mechanism
AACR Annual Meeting 2018
Dianhydrogalactitol (VAL-083) has a distinct mechanism of action that suggests combination with PARP inhibitors as an effective therapeutic strategy